1. Home
  2. PNI vs MXCT Comparison

PNI vs MXCT Comparison

Compare PNI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco New York Municipal Income Fund II of Beneficial Interest

PNI

Pimco New York Municipal Income Fund II of Beneficial Interest

HOLD

Current Price

$7.00

Market Cap

79.1M

Sector

Finance

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$0.84

Market Cap

93.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNI
MXCT
Founded
2002
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.1M
93.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PNI
MXCT
Price
$7.00
$0.84
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
40.4K
632.6K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
4.76%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.43
$0.64
52 Week High
$7.20
$2.86

Technical Indicators

Market Signals
Indicator
PNI
MXCT
Relative Strength Index (RSI) 56.41 51.60
Support Level $6.88 $0.65
Resistance Level $7.07 $0.89
Average True Range (ATR) 0.08 0.05
MACD 0.00 -0.00
Stochastic Oscillator 73.68 47.77

Price Performance

Historical Comparison
PNI
MXCT

About PNI Pimco New York Municipal Income Fund II of Beneficial Interest

PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: